Corona vaccine test stopped: Subject probably suffering from a rare disease - first suspicion is in the room

As one of nine pharmaceutical companies worldwide, AstraZeneca is in the crucial test phase for a corona vaccine.

But the study has to be suspended.

• AstraZeneca

  is considered to be a great hope in the development of a

  corona vaccine

  .

• But now the British-Swedish pharmaceutical company has

  to stop the clinical test phase

  .

• Here you will find the basic facts about the coronavirus * and the corona news from Germany.

  We also offer you the current number of cases in Germany on a map.

Munich - All over the world people long for a

to be able to fight the corona pandemic * effectively.

A company is well advanced in developing a serum.

The British-Swedish pharmaceutical company

is one of nine companies worldwide in the third and final phase of clinical studies and is considered to be a great hope.

Tests with tens of thousands of participants were running.

Corona vaccine: AstraZeneca has to interrupt the test phase

But in the race to get a vaccine * approved,

now suffered a major setback.

because one of the subjects had health problems

This is a routine measure "that must be carried out whenever a potentially inexplicable disease occurs in one of the studies," said a company spokesman.

He went on to say that the process had been voluntarily interrupted "in order to enable the safety data to be checked by an independent committee."

Tests for corona vaccine interrupted: patient is said to have rare neurological disease

did not provide any information

about the disease or where the patient is

.

But there are conjectures and rumors.

The

to have learned from an informed person that the patient is said to have transverse myelitis.

This is a rare neurological disorder caused by inflammation of the central nervous system caused by viruses.

Breaking News: A major coronavirus vaccine trial was halted because of a serious adverse reaction in a participant, the pharmaceutical company AstraZeneca said.

https://t.co/PC4EYqPr1c

- The New York Times (@nytimes) September 8, 2020

The

active ingredient AZD1222 manufactured

by

is based on the weakened version of a cold virus from chimpanzees and is supposed to get the immune system going so that it can fight Sars-CoV-2 * in the event of infection.

List of rubric lists: © Ted S. Warren / dpa